|
1.
|
|
19 p, 837.6 KB |
Malignant bone tumors (other than Ewing's) : clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
/
Redondo, Andrés (Hospital Universitario La Paz (Madrid)) ;
Bagué Rosell, Sílvia (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabeu, Daniel (Hospital Universitario La Paz (Madrid)) ;
Ortiz-Cruz, Eduardo (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa)) ;
Lopez-Martin, Jose A. (Hospital 12 de Octubre (Madrid)) ;
Correa, Raquel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cruz, Josefina (Hospital Universitario de Canarias (La Laguna)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Santos, Aurelio (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García del Muro, Xavier (Institut Catalá d'Oncologia Hospitalet) ;
Martin-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Universitat Autònoma de Barcelona
Primary malignant bone tumors are uncommon and heterogeneous malignancies. This document is a guideline developed by the Spanish Group for Research on Sarcoma with the participation of different specialists involved in the diagnosis and treatment of bone sarcomas. [...]
2017 -  10.1007/s00280-017-3436-0
Cancer Chemotherapy and Pharmacology, Vol. 80 Núm. 6 (january 2017) , p. 1113-1131
|
|
|
2.
|
|
11 p, 529.4 KB |
Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial
/
Martin-Broto, J. (Universidad de Sevilla) ;
Hindi, Nadia (Universidad de Sevilla) ;
Grignani, G. (Candiolo Cancer Institute) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Redondo, A. (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Stacchiotti, S. (Istituto Nazionale Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
D'Ambrosio, L. (Candiolo Cancer Institute) ;
Gutierrez, A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Perez-Vega, H. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Encinas-Tobajas, V. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
De Álava, Enrique (Universidad de Sevilla) ;
Collini, Paola (Istituto Nazionale Tumori) ;
Peña-Chilet, M. (Hospital Virgen Del Rocio) ;
Dopazo, J. (Hospital Virgen Del Rocío) ;
Carrasco-Garcia, I. (Universidad de Sevilla) ;
Lopez-Alvarez, M. (Universidad de Sevilla) ;
Moura, D.S. (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. [...]
2020 - 10.1136/jitc-2020-001561
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (17 2020) , p. e001561
|
|
|
3.
|
|
10 p, 1.1 MB |
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
García-Martínez, E. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martinez, M. (Hospital del Mar (Barcelona, Catalunya)) ;
Muñoz Couselo, Eva (Vall d'Hebron Institut d'Oncologia) ;
Rodriguez-Abreu, D. (C.H.U. Insular-Materno Infantil de Gran Canaria) ;
Alvarez, R. (Hospital Virgen de la Salud (Toledo)) ;
Arance, Ana (Hospital Clínic i Provincial de Barcelona) ;
Berrocal, A. (Hospital General Universitario de Valencia) ;
de la Cruz Merino, Luis (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. [...]
2020 - 10.1007/s12094-019-02273-x
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 213-222
|
|
|
4.
|
|
11 p, 765.0 KB |
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
/
Martin-Broto, Javier (Universidad Autónoma de Madrid) ;
Redondo, Andres (Hospital Universitario La Paz (Madrid)) ;
Moura, David S. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Morales, Jose Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet. Servicio de Oncología Médica) ;
Gutierrez, Antonio (Hospital Universitario Son Espases. Servicio de Hematología) ;
Díaz-Beveridge, Roberto (Hospital Universitari i Politècnic La Fe (València)) ;
Luna, Pablo (Hospital Universitario Son Espases. Servicio de Oncología Médica) ;
Martinez-Marin, Virginia (Hospital Universitario La Paz (Madrid)) ;
Marcilla, David (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Arribas, Ivan (Universitat de València) ;
Ledesma, Patricio (Sofpromed Investigacion Clinica SLU) ;
Lopez-Martin, Jose A. (Hospital Universitario 12 de Octubre (Madrid)) ;
Di Lernia, Davide (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Zamora, Jorge (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Hindi, Nadia (Universidad Autónoma de Madrid)
Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. [...]
2022 - 10.1038/s41467-022-33975-6
Nature communications, Vol. 13 Núm. 1 (december 2022) , p. 6278
|
|
|
5.
|
|
8 p, 1.0 MB |
Plitidepsin in adult patients with COVID-19 requiring hospital admission : A long-term follow-up analysis
/
Varona, Jose F. (Universidad San Pablo-Centro de Estudios Universitarios (CEU)) ;
Landete, Pedro (Universidad Autónoma de Madrid) ;
Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Vates, Roberto (Hospital Universitario de Getafe (Madrid)) ;
Torralba, Miguel (Universidad de Alcalá) ;
Guisado-Vasco, Pablo (Universidad Europea de Madrid) ;
Porras, Lourdes (Hospital General de Ciudad Real) ;
Muñoz, Patricia (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Gijon, Paloma (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Ancochea, Julio (Universidad Autónoma de Madrid) ;
Saiz, Elena (Virology Unit, PharmaMar, SA) ;
Meira, Fernanda (PharmaMar, SA) ;
Jimeno, Jose M. (PharmaMar, SA) ;
Lopez-Martin, Jose A. (PharmaMar, SA) ;
Estrada, Vicente (Universidad Complutense de Madrid) ;
Universitat Autònoma de Barcelona
The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated and any long-term complications were characterized. [...]
2023 - 10.3389/fcimb.2023.1097809
Frontiers in cellular and infection microbiology, Vol. 13 (february 2023)
|
|
|
6.
|
|
22 p, 3.1 MB |
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
/
Varona, Jose F. (Universidad San Pablo-CEU. Facultad de Medicina, Madrid) ;
Landete, Pedro (Universidad Autónoma de Madrid) ;
Lopez-Martin, Jose A. (Virology and Inflammation Unit, PharmaMar, SA, Madrid) ;
Estrada, Vicente (Universidad Complutense de Madrid) ;
Paredes, Roger (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Guisado-Vasco, Pablo (Universidad Europea de Madrid) ;
Fernandez de Orueta, Lucia (Hospital Universitario de Getafe (Madrid)) ;
Torralba, Miguel (Hospital Universitario de Guadalajara) ;
Fortún, Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ;
Vates, Roberto (Hospital Universitario de Getafe (Madrid)) ;
Barberán, José (Facultad de Medicina, Universidad San Pablo-CEU, Madrid) ;
Clotet Sala, Bonaventura (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ancochea, Julio (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias) ;
Carnevali, Daniel (Universidad Europea de Madrid) ;
Cabello, Noemi (Hospital Clínico San Carlos (Madrid)) ;
Porras, Lourdes (Hospital General Universitario de Ciudad Real) ;
Gijon, Paloma (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Monereo, Alfonso (Hospital Universitario de Getafe (Madrid)) ;
Abad, Daniel (Hospital Universitario de Getafe (Madrid)) ;
Zuñiga, Sonia (Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid) ;
Sola, Isabel (Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid) ;
Rodon, Jordi (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ;
Vergara-Alert, Júlia (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ;
Izquierdo Useros, Nuria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fudio, Salvador (Clinical Pharmacology Unit, PharmaMar, Madrid) ;
Pontes, Maria Jose (Medical Affairs, PharmaMar, Madrid) ;
de Rivas, Beatriz (Medical Affairs, PharmaMar, Madrid) ;
Giron de Velasco, Patricia (Virology and Inflammation Unit, PharmaMar, Madrid) ;
Nieto, Antonio (Bio Statistics Unit, PharmaMar, Madrid) ;
Gomez, Javier (Bio Statistics Unit, PharmaMar, Madrid) ;
Avilés, Pablo (Preclinical Unit, Pharmamar, Madrid) ;
Lubomirov, Rubin (Clinical Pharmacology Unit, PharmaMar, Madrid) ;
Belgrano, Alvaro (Bio Statistics Unit, PharmaMar, Madrid) ;
Sopesen, Belen (Biocross, SL, Valladolid) ;
White, Kris M. (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ;
Rosales, Romel (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ;
Yildiz, Soner (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ;
Reuschl, Ann-Kathrin (Division of Infection and Immunity, University College London) ;
Thorne, Lucy G. (Division of Infection and Immunity, University College London, London, UK) ;
Jolly, Clare (Division of Infection and Immunity, University College London) ;
Towers, Greg J. (Division of Infection and Immunity, University College London) ;
Zuliani-Alvarez, Lorena (Department of Cellular and Molecular Pharmacology, University of California, San Francisco) ;
Bouhaddou, Mehdi (Department of Cellular and Molecular Pharmacology, University of California, San Francisco) ;
Obernier, Kirsten (Department of Cellular and Molecular Pharmacology, University of California, San Francisco) ;
McGovern, Briana L. (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ;
Rodriguez, M. Luis (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ;
Enjuanes, Luis (Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid) ;
Fernandez-Sousa, Jose M. (Pharmamar, Madrid) ;
Krogan, Nevan J. (Department of Cellular and Molecular Pharmacology, University of California, San Francisco) ;
Jimeno, Jose M. (Virology and Inflammation Unit, PharmaMar, SA, Madrid) ;
Garcia-Sastre, Adolfo (Icahn School of Medicine at Mount Sinai, New York)
This proof-of-concept study shows that plitidepsin, a marine peptide that inhibits SARS-CoV-2 replication, has a favorable safety profile and may be an efficacious treatment for patients with COVID-19. [...]
2022 - 10.26508/lsa.202101200
Life Science Alliance, Vol. 5 (january 2022)
|
|
|
7.
|
|
5 p, 753.9 KB |
Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer
/
Puig Rosell, Pere (R&D Department, Atrys Health) ;
Erill, Nadina (R&D Department, Atrys Health) ;
Terricabras, Marta (R&D Department, Atrys Health) ;
Subirana, Isaac (R&D Department, Atrys Health) ;
González-García, Judit (R&D Department, Atrys Health) ;
Asensi-Puig, Adrià (R&D Department, Atrys Health) ;
Donovan, Michael J. (Icahn School of Medicine at Mount Sinai, MSSM) ;
Mengual, Lourdes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Agulló-Ortuño, M. Teresa (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology) ;
Olivan, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Alcaraz, Antonio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lopez-Martin, Jose A (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology) ;
de Torres, Inés (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rodríguez-Peralto, José Luis (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology) ;
Rodríguez-Antolín, Alfredo (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology) ;
Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
González-Rumayor, Víctor (R&D Department, Atrys Health) ;
Universitat Autònoma de Barcelona
To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. [...]
2019 - 10.1186/s13104-019-4100-z
BMC research notes, Vol. 12 (january 2019)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
